Shanghai Kehua Bio-Engineering Co Ltd

KHB's wholly owned subsidiary, KHB Xi'an Bioengineering Co., Ltd., has recently obtained two medical device registration certificates issued by the Shaanxi Provincial Medical Products Administration. The registration certificate number for the progesterone assay kit is Shaanxi Medical Device Registration Permit 20262400148, and the registration certificate number for the D-dimer assay kit is Shaanxi Medical Device Registration Permit 20262400149, both valid until August 19, 2031. The company stated that obtaining the registration certificates for these products has enriched its product line and will have a positive impact on business development, but it is still unable to predict the impact on future operating revenue.

Kehua Bio-Science announced that the company recently received a medical device registration certificate from the National Medical Products Administration for its Neisseria gonorrhoeae nucleic acid detection kit, which uses PCR-fluorescence method. The certificate is valid from August 4, 2026 to August 3, 2031. The kit is used for in vitro qualitative detection of Neisseria gonorrhoeae nucleic acid in male urethral swab and female cervical swab samples. The company stated that the acquisition of this product enriches its product line and will have a positive impact on business development.

Kehua Bio has released a draft of its 2026 restricted stock incentive plan, proposing to grant a total of 20 million shares, representing approximately 3.89% of the company's total share capital. Of these, 17 million shares will be granted initially, accounting for about 3.30% of the total share capital, and 3 million shares will be reserved for future grants, representing about 0.58% of the total share capital. The grant price is 2.57 yuan per share. The incentive recipients include no more than six company directors and senior management personnel. In the first quarter of 2026, Kehua Bio achieved revenue of 395 million yuan and a net loss attributable to the parent company of 48.45 million yuan.

KHB announced that it recently received a medical device registration certificate from the Shanghai Medical Products Administration for its Complement C1q Assay Kit (latex immunoturbidimetric method), valid until June 29, 2031. The product is used for the in vitro quantitative determination of complement C1q in human serum and plasma. It will enrich the company's product line and have a positive impact on business development, though the specific revenue impact cannot yet be predicted.